A review of antimicrobial stability testing guidance for outpatient parenteral antimicrobial therapy programmes: is it time for global harmonization of testing frameworks?

For most antimicrobials, a 5%–10% API loss may not be significant given this threshold comfortably exists within routinely observed between-patient pharmacokinetic variation. 36 There is significant evidence of the benefits of continuous infusions in critically ill patients; however, the outcomes of use in OPAT are unknown. 37 Nevertheless, for those antimicrobials where degradation products are toxic, the effect may be clinically relevant and the patient effects worth investigation.

also in 2,774 other papers